##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 155 No. 4 (2025)

Hereditary alpha-tryptasemia – a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases

Cite this as:
Swiss Med Wkly. 2025;155:3679
Published
02.04.2025

Summary

Hereditary alpha-tryptasemia (HAT) is an autosomal dominant genetic trait affecting 4% to 6% of the general population. Hereditary alpha-tryptasemia is caused by an excess of alpha tryptase encoding TPSAB1 copy numbers on one parenteral allele, most often duplications or triplications, leading to elevated levels of basal serum tryptase. There might be a gene dosage effect between the number of additional TPSAB1 copies, the level of basal serum tryptase and the severity of clinical symptoms, including atopic, cutaneous, gastrointestinal, musculoskeletal, autonomic and neuropsychiatric manifestations. Hereditary alpha-tryptasemia is a potential risk factor for severe anaphylactic reactions. The prevalence of hereditary alpha-tryptasemia is higher in patients with systemic mastocytosis. In the diagnostic workup of patients with anaphylactic reactions and symptoms of mast cell mediator release after measurement of basal serum tryptase, it is therefore essential to screen for both the KIT D816V activating point mutation and hereditary alpha-tryptasemia by droplet digital polymerase chain reaction. Such a diagnostic approach can identify patients with hereditary alpha-tryptasemia, which may allow the avoidance of further diagnostic workup with bone marrow examination. Moreover, it can identify patients at high risk of anaphylactic reactions. So far, no targeted therapy for hereditary alpha-tryptasemia is available. Treatment for symptom control consists of H1- and H2-blockers, leukotriene antagonists and cromoglicic acid. Urticaria and anaphylaxis are especially successfully treated with the monoclonal anti-IgE-antibody omalizumab in patients with hereditary alpha-tryptasemia. H1-blockers and steroids are sufficient in emergencies. As hereditary alpha-tryptasemia is a hereditary condition, first-degree relatives with anaphylactic reactions or symptoms of mast cell mediator release should be tested for hereditary alpha-tryptasemia after measurement of basal serum tryptase.

References

  1. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021. 13;5(11):e646. doi: 10.1097/HS9.0000000000000646.
  2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703–19. 10.1038/s41375-022-01613-1
  3. Weiler CR, Austen KF, Akin C, Barkoff MS, Bernstein JA, Bonadonna P, et al. AAAAI Mast Cell Disorders Committee Work Group Report: mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019 Oct;144(4):883–96. doi: https://doi.org/10.1016/j.jaci.2019.08.023
  4. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002 Jun;128(2):136–41. doi: https://doi.org/10.1159/000059404
  5. Sirvent AE, González C, Enríquez R, Fernández J, Millán I, Barber X, et al. Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease. J Nephrol. 2010;23(3):282–90.
  6. Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 2001 Oct;98(7):2200–9. doi: https://doi.org/10.1182/blood.V98.7.2200
  7. Siles R, Xu M, Hsieh FH. The utility of serum tryptase as a marker in chronic spontaneous urticaria. Acta Derm Venereol. 2013 May;93(3):354–5. doi: https://doi.org/10.2340/00015555-1486
  8. Lyons JJ, Greiner G, Hoermann G, Metcalfe DD. Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1964–73. doi: https://doi.org/10.1016/j.jaip.2022.05.003
  9. Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma. 2002 May;43(5):1097–105. doi: https://doi.org/10.1080/10428190290021470
  10. Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest. 2009 Oct;39(10):914–23. doi: https://doi.org/10.1111/j.1365-2362.2009.02184.x
  11. Lyons JJ. Hereditary alpha tryptasemia: genotyping and associated clinical features. Immunol Allergy Clin North Am. 2018 Aug;38(3):483–95. doi: https://doi.org/10.1016/j.iac.2018.04.003
  12. Schwartz LB, Min HK, Ren S, Xia HZ, Hu J, Zhao W, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol. 2003 Jun;170(11):5667–73. doi: https://doi.org/10.4049/jimmunol.170.11.5667
  13. Lyons JJ, Chovanec J, O’Connell MP, Liu Y, Šelb J, Zanotti R, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2021 Feb;147(2):622–32. doi: https://doi.org/10.1016/j.jaci.2020.06.035
  14. Zhang H, Zeng X, He S. Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation. Mediators Inflamm. 2014;2014:829068. doi: https://doi.org/10.1155/2014/829068
  15. Ong MS, Tergaonkar V. When alpha meets beta, mast cells get hyper. J Exp Med. 2019 Oct;216(10):2229–30. doi: https://doi.org/10.1084/jem.20191169
  16. Melo FR, Wallerman O, Paivandy A, Calounova G, Gustafson AM, Sabari BR, et al. Tryptase-catalyzed core histone truncation: A novel epigenetic regulatory mechanism in mast cells. J Allergy Clin Immunol. 2017 Aug;140(2):474–85. doi: https://doi.org/10.1016/j.jaci.2016.11.044
  17. Gotlib J, Horny HP, Valent P. Mast cells and mastocytosis. In: Hoffman R, Benz JE, editors. Hematology. Basic Principles and Practice. 7th ed. Elsevier; 2018. pp. 1170–86.
  18. Chovanec J, Tunc I, Hughes J, Halstead J, Mateja A, Liu Y, et al. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv. 2023 May;7(9):1796–810. doi: https://doi.org/10.1182/bloodadvances.2022007936
  19. O’Connell MP, Lyons JJ. Resolving the genetics of human tryptases: implications for health, disease, and clinical use as a biomarker. Curr Opin Allergy Clin Immunol. 2022 Apr;22(2):143–52. doi: https://doi.org/10.1097/ACI.0000000000000813
  20. Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016 Dec;48(12):1564–9. doi: https://doi.org/10.1038/ng.3696
  21. Robey RC, Wilcock A, Bonin H, Beaman G, Myers B, Grattan C, et al. Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease Expression. J Allergy Clin Immunol Pract. 2020;8(10):3549–56. doi: https://doi.org/10.1016/j.jaip.2020.05.057
  22. Glover SC, Carter MC, Korošec P, Bonadonna P, Schwartz LB, Milner JD, et al. Clinical relevance of inherited genetic differences in human tryptases: hereditary alpha-tryptasemia and beyond. Ann Allergy Asthma Immunol. 2021 Dec;127(6):638–47. doi: https://doi.org/10.1016/j.anai.2021.08.009
  23. Atiakshin D, Buchwalow I, Samoilova V, Tiemann M. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol. 2018 May;149(5):461–77. doi: https://doi.org/10.1007/s00418-018-1659-8
  24. Shaker MS, Wallace DV, Golden DB, Oppenheimer J, Bernstein JA, Campbell RL, et al.; Collaborators; Chief Editors; Workgroup Contributors; Joint Task Force on Practice Parameters Reviewers. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082–123. doi: https://doi.org/10.1016/j.jaci.2020.01.017
  25. Greiner G, Sprinzl B, Górska A, Ratzinger F, Gurbisz M, Witzeneder N, et al. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood. 2021 Jan;137(2):238–47. doi: https://doi.org/10.1182/blood.2020006157
  26. González-de-Olano D, Navarro-Navarro P, Muñoz-González JI, Sánchez-Muñoz L, Henriques A, de-Andrés-Martín A, et al. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals. Allergy. 2024 Mar;79(3):711–23. doi: https://doi.org/10.1111/all.15911
  27. Sabato V, Chovanec J, Faber M, Milner JD, Ebo D, Lyons JJ. First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease. J Clin Immunol. 2018 May;38(4):457–9. doi: https://doi.org/10.1007/s10875-018-0506-y
  28. Valent P, Hoermann G, Bonadonna P, Hartmann K, Sperr WR, Broesby-Olsen S, et al. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT. J Allergy Clin Immunol Pract. 2023 Oct;11(10):3010–20. doi: https://doi.org/10.1016/j.jaip.2023.08.008
  29. Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B, et al. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1953–63. doi: https://doi.org/10.1016/j.jaip.2022.03.001
  30. Sotlar K, George TI, Kluin P, Reiter A, Schwaab J, Panse J, et al. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1986–1998.e2. doi: https://doi.org/10.1016/j.jaip.2022.05.036
  31. Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015 Jun;29(6):1223–32. doi: https://doi.org/10.1038/leu.2015.24
  32. Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015 Jul;136(1):135–9. doi: https://doi.org/10.1016/j.jaci.2014.11.035
  33. von Bubnoff D, Koch D, Stocker H, Ludwig RJ, Wortmann F, von Bubnoff N. The Clinical Features of Hereditary Alpha-Tryptasemia—Implications for Interdisciplinary Practice. Dtsch Arztebl Int. 2024 Apr;121(8):258–64.
  34. Mendoza Alvarez LB, Barker R, Nelson C, DiMaggio T, Stone KD, Milner JD, et al. Clinical response to omalizumab in patients with hereditary α-tryptasemia. Ann Allergy Asthma Immunol. 2020 Jan;124(1):99–100.e1. doi: https://doi.org/10.1016/j.anai.2019.09.026
  35. Giannetti MP, Weller E, Bormans C, Novak P, Hamilton MJ, Castells M. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. Ann Allergy Asthma Immunol. 2021 Jun;126(6):655–60. doi: https://doi.org/10.1016/j.anai.2021.01.016